Alvotech and Polifarma sign agreement to commercialise AVT06 in Turkey
10 May 2023
License out/inBiosimilar
Preview
Source: Pharmaceutical Technology
Alvotech commenced a trial in July 2022 to compare AVT06 and Eylea for the treatment of adults with neovascular (wet) age-related macular degeneration. Credit: Richard Leung/Kings College Hospital / Community Eye Health / Flickr (Creative Commons)
Alvotech has signed an exclusive agreement with Polifarma to commercialise AVT06, a planned biosimilar to Eylea (aflibercept), in Turkey.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsTurkey - Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and C... GlobalData
Preview
Source: Pharmaceutical Technology
ReportsPharmaceuticals Industry Deals and Trends in November 2021 - Partnerships, Licensing, Investments... GlobalData
View allCompanies IntelligenceAlvotech SAPolifarma IIac San ve Tic ASView all
In July 2022, Alvotech commenced a trial to compare AVT06 and Eylea for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD).
The trial has been designed to assess the efficacy, safety and immunogenicity of the therapy combination in the targeted patients.
Alvotech chairman and CEO Robert Wessman stated: “It is a pleasure to join forces with Polifarma in the commercialisation of a potential therapy in eye disease.
“We are committed to providing better patient access to affordable biologics, and this agreement will allow us to better serve the growing and important Turkish market.”
The latest deal comes a month after Alvotech received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for its biologics licence application (BLA) for AVT02, a biosimilar to Humira (adalimumab).
“This agreement with Alvotech allows us to expand our portfolio and further strengthen our position in the ophthalmology area.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.